Abstract Background Biosimilars account for 30–40% of biologic medications dispensed in
the United States (US), yet healthcare providers in relevant medical specialties have limited …

Background Biosimilars can improve patient access to biological medicines. Although
biosimilars have been shown to be equally effective and safe, some patients remain …

Background Knowledge, attitudes and substitution laws of biosimilars are not consistent
across countries. Biosimilar acceptance among patients and healthcare professionals may …

Zusammenfassung Auf einen Blick Biosimilars gelten als ein vielversprechender Ansatz, um
leistbaren und nachhaltigen Zugang zu biologischen Arzneimitteln zu ermöglichen. Um den …

Biopharmaceutical manufacturers have been prompted by high costs and patent expiration
of biologicals to explore development of biosimilars. The lower costs of biosimilars makes …

Biosimilars, medicines highly similar to another already approved biological medicine, are
cost-effective alternatives to biologicals and are crucial for healthcare accessibility. While …